New drug approved on NHS reduces risk of relapse of rare blood cancer by a quarter

New drug approved on NHS reduces risk of relapse of rare blood cancer by a quarter NHS patients being treated for an aggressive type of blood cancer will now benefit from a potent drug that can slash the risk of their disease returning.

Experts say that the medicine, called Polivy, could drastically improve survival rates for the 5,000 Britons who each year develop the condition, diffuse large B-cell lymphoma. A third of sufferers don't survive more than five years after diagnosis. The Daily Mail

See also:

• Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma NICE